Key result
HCV IRES offers a potential antiviral target by driving cap-independent viral protein synthesis.
Why the study?
There is no effective treatment available for hepatitis C virus infection, and its replication depends on a unique translation-initiation mechanism involving the viral internal ribosome-entry site.
The hepatitis C virus internal ribosome-entry site (IRES) represents a potential target for novel antiviral therapies due to its unique role in cap-independent translation initiation.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for IRES-targeted antivirals in HCV; clinical trials needed before therapeutic consideration.
The hepatitis C virus (HCV) is the main causative agent of non-A, non-B hepatitis in humans and a major cause of mortality and morbidity in the world. Currently there is no effective treatment available for the infection caused by this virus, whose replication depends on an unusual translation-initiation mechanism. The viral RNA contains an internal ribosome-entry site (IRES) that is recognized specifically by the small ribosomal subunit and by eukaryotic initiation factor 3, and these interactions allow cap (7-methyl-guanine nucleotide)-independent initiation of viral protein synthesis. In this article, we review the structure and mechanism of translation initiation of the HCV IRES, and its potential as a target for novel antivirals.
No takes yet. Share an insight, caveat, or question.
Gallego et al. (2002) conducted a review in Hepatitis C virus infection. HCV IRES targeted antivirals was evaluated. The hepatitis C virus internal ribosome-entry site (IRES) presents a potential target for novel antiviral research due to its essential role in cap-independent initiation of viral protein synthesis.
Synapse has enriched 10 related papers. Consider them for comparative context: